Patents by Inventor Mark Leo Michaels

Mark Leo Michaels has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FGF21 Mutants and Uses Thereof
    Publication number: 20240076333
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: November 1, 2023
    Publication date: March 7, 2024
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, JIng Xu
  • VARIANTS OF TISSUE INHIBITOR OF METALLOPROTEINASE TYPE THREE (TIMP-3), COMPOSITIONS AND METHODS
    Publication number: 20240010708
    Abstract: There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.
    Type: Application
    Filed: August 28, 2023
    Publication date: January 11, 2024
    Applicant: AMGEN INC.
    Inventors: Jeonghoon SUN, Jason Charles O'NEILL, Randal R. KETCHEM, Randy Ira HECHT, Edward J. BELOUSKI, Mark Leo MICHAELS
  • Methods of treating non-alcoholic steatohepatitis using FGF21 mutants
    Patent number: 11840558
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: December 12, 2023
    Assignee: AMGEN INC.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • STABILIZED RECEPTOR POLYPEPTIDES AND USES THEREOF
    Publication number: 20230295267
    Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
    Type: Application
    Filed: June 7, 2023
    Publication date: September 21, 2023
    Applicant: AMGEN INC.
    Inventors: Jeonghoon SUN, Lei-Ting Tony TAM, Mark Leo MICHAELS, Thomas Charles BOONE, Rohini R. DESHPANDE, Yue-Sheng LI, Huiquan HAN
  • Stabilized receptor polypeptides and uses thereof
    Patent number: 11685770
    Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: June 27, 2023
    Assignee: Amgen Inc.
    Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Mark Leo Michaels, Thomas Charles Boone, Rohini Deshpande, Yue-Sheng Li, Huiquan Han
  • ANTI-CGRP RECEPTOR/ANTI-PAC1 RECEPTOR BISPECIFIC ANTIGEN BINDING PROTEINS
    Publication number: 20220363770
    Abstract: The present invention relates to antagonist antibodies of the human calcitonin gene-related peptide (CGRP) receptor as well as bispecific antigen binding proteins derived from the anti-CGRP antibodies that bind to and inhibit both the human CGRP receptor and another target, such as the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) receptor. Pharmaceutical compositions comprising the anti-CGRP receptor antibodies and bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the anti-CGRP receptor antibodies and bispecific antigen binding proteins to ameliorate, treat, or prevent conditions associated with the CGRP and PAC1 receptors, such as chronic pain, migraine, and cluster headache, are also described.
    Type: Application
    Filed: June 26, 2020
    Publication date: November 17, 2022
    Applicant: AMGEN INC.
    Inventors: Irwin CHEN, Su CHONG, Fernando GARCES, Mark Leo MICHAELS, Christopher MOHR, Kenneth William WALKER, Zhulun WANG, Neeraj Jagdish AGRAWAL, Bryna FUCHSLOCHER, Kevin GRAHAM, Agnes Eva HAMBURGER, Derek E. PIPER, Cen XU
  • PAC1 ANTIBODIES AND USES THEREOF
    Publication number: 20220195022
    Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
    Type: Application
    Filed: December 21, 2021
    Publication date: June 23, 2022
    Applicant: AMGEN INC.
    Inventors: Neeraj Jagdish AGRAWAL, Irwin CHEN, Su CHONG, Bryna FUCHSLOCHER, Kevin GRAHAM, Agnes Eva HAMBURGER, Mark Leo MICHAELS, Christopher MOHR, Derek E. PIPER, Kenneth William WALKER, Zhulun WANG, Cen XU
  • FG21 MUTANTS AND USES THEREOF
    Publication number: 20210317176
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: June 24, 2021
    Publication date: October 14, 2021
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • Methods of treating non-alcoholic steatohepatitis using FGF21 mutants
    Patent number: 11072640
    Abstract: The invention provides methods for treating non-alcoholic steatohepatitis (NASH) using FGF21 mutant polypeptides.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: July 27, 2021
    Assignee: AMGEN INC.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • PAC1 ANTIBODIES AND USES THEREOF
    Publication number: 20210017261
    Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
    Type: Application
    Filed: July 1, 2020
    Publication date: January 21, 2021
    Applicant: AMGEN INC.
    Inventors: Neeraj Jagdish AGRAWAL, Irwin CHEN, Su CHONG, Bryna FUCHSLOCHER, Kevin GRAHAM, Agnes Eva HAMBURGER, Mark Leo MICHAELS, Christopher MOHR, Derek E. PIPER, Kenneth William WALKER, Zhulun WANG, Cen XU
  • STABILIZED RECEPTOR POLYPEPTIDES AND USES THEREOF
    Publication number: 20200283504
    Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
    Type: Application
    Filed: April 18, 2019
    Publication date: September 10, 2020
    Inventors: Jeonghoon SUN, Lei-Ting Tony TAM, Mark Leo MICHAELS, Thomas Charles BOONE, Rohini DESHPANDE, Yue-Sheng LI, Huiquan HAN
  • STABILIZED RECEPTOR POLYPEPTIDES AND USES THEREOF
    Publication number: 20190389932
    Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
    Type: Application
    Filed: April 18, 2019
    Publication date: December 26, 2019
    Inventors: Jeonghoon SUN, Lei-Ting Tony TAM, Mark Leo MICHAELS, Thomas Charles BOONE, Rohini DESHPANDE, Yue-Sheng LI, Huiquan HAN
  • PAC1 ANTIBODIES AND USES THEREOF
    Publication number: 20190218279
    Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
    Type: Application
    Filed: January 11, 2019
    Publication date: July 18, 2019
    Applicant: AMGEN INC.
    Inventors: Neeraj Jagdish AGRAWAL, Irwin CHEN, Su CHONG, Bryna FUCHSLOCHER, Kevin GRAHAM, Agnes Eva HAMBURGER, Mark Leo MICHAELS, Christopher MOHR, Derek E. PIPER, Kenneth William WALKER, Zhulun WANG, Cen XU
  • Isolated nucleic acid molecules encoding stabilized receptor polypeptides and uses thereof
    Patent number: 10308704
    Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: June 4, 2019
    Assignee: Amgen Inc.
    Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Mark Leo Michaels, Thomas Charles Boone, Rohini Deshpande, Yue-Sheng Li, Huiquan Han
  • VARIANTS OF TISSUE INHIBITOR OF METALLOPROTEINASE TYPE THREE (TIMP-3), COMPOSITIONS AND METHODS
    Publication number: 20190085054
    Abstract: There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.
    Type: Application
    Filed: December 4, 2018
    Publication date: March 21, 2019
    Inventors: Jeonghoon Sun, Jason Charles O'Neill, Randal R. Ketchem, Randy Ira Hecht, Edward J. Belouski, Mark Leo Michaels
  • Variants of tissue inhibitor of metalloproteinase type three (TIMP-3), compositions and methods
    Patent number: 10189890
    Abstract: There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: January 29, 2019
    Assignee: Amgen Inc.
    Inventors: Jeonghoon Sun, Jason Charles O'Neill, Randal R. Ketchem, Randy Ira Hecht, Edward J. Belouski, Mark Leo Michaels
  • FGF21 Mutants and Uses Thereof
    Publication number: 20190023757
    Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
    Type: Application
    Filed: June 1, 2018
    Publication date: January 24, 2019
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • Methods of treating of diabetes and obesity using FGF21 mutants
    Patent number: 10011642
    Abstract: The invention provides methods of treating diabetes, reducing triglyceride levels, and treating obesity by administering to a subject in need there a fusion protein comprising an FGF21 mutant.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: July 3, 2018
    Assignee: AMGEN INC.
    Inventors: Edward John Belouski, Murielle Marie Ellison, Agnes Eva Hamburger, Randy Ira Hecht, Yue-Sheng Li, Mark Leo Michaels, Jeonghoon Sun, Jing Xu
  • Inhibitory polypeptides specific to WNT inhibitors
    Patent number: 9708375
    Abstract: The present application is directed to avimers and peptides and various combinations thereof in addition to methods of making and using them.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 18, 2017
    Assignee: Amgen Inc.
    Inventors: Ryan B. Case, Benjamin M. Alba, Alice Bakker, Irwin Chen, Amy N. Duguay, Monica Florio, Peng Li, Mark Leo Michaels, Mei-Mei Tsai
  • Stabilized Receptor Polypeptides and Uses Thereof
    Publication number: 20170183391
    Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
    Type: Application
    Filed: January 22, 2016
    Publication date: June 29, 2017
    Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Mark Leo Michaels, Thomas Charles Boone, Rohini Deshpande, Yue-Sheng Li, Huiquan Han